Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$164.16 USD
-0.66 (-0.40%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $163.98 -0.18 (-0.11%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Price, Consensus and EPS Surprise
JNJ 164.16 -0.66(-0.40%)
Will JNJ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
Other News for JNJ
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
Attorneys Vow to Oppose J&J?s Third Bankruptcy Attempt
Johnson & Johnson's Red River Talc files for Chapter 11 bankruptcy
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims